These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 23739246)

  • 1. Low incidence of oncogenic EGFR, HRAS, and KRAS mutations in seborrheic keratosis.
    Georgieva IA; Mauerer A; Groesser L; Herschberger E; Aslanidis C; Dietmaier W; Landthaler M; Hafner C
    Am J Dermatopathol; 2014 Aug; 36(8):635-42. PubMed ID: 23739246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The mutational spectrum of HRAS, KRAS, NRAS and FGFR3 genes in bladder cancer.
    Ouerhani S; Elgaaied AB
    Cancer Biomark; 2011-2012; 10(6):259-66. PubMed ID: 22820081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FGFR3, PIK3CA and RAS mutations in benign lichenoid keratosis.
    Groesser L; Herschberger E; Landthaler M; Hafner C
    Br J Dermatol; 2012 Apr; 166(4):784-8. PubMed ID: 22188534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PIK3CA, HRAS and KRAS gene mutations in human penile cancer.
    Andersson P; Kolaric A; Windahl T; Kirrander P; Söderkvist P; Karlsson MG
    J Urol; 2008 May; 179(5):2030-4. PubMed ID: 18355852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple oncogenic mutations and clonal relationship in spatially distinct benign human epidermal tumors.
    Hafner C; Toll A; Fernández-Casado A; Earl J; Marqués M; Acquadro F; Méndez-Pertuz M; Urioste M; Malats N; Burns JE; Knowles MA; Cigudosa JC; Hartmann A; Vogt T; Landthaler M; Pujol RM; Real FX
    Proc Natl Acad Sci U S A; 2010 Nov; 107(48):20780-5. PubMed ID: 21078999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatic FGFR3 and PIK3CA mutations are present in familial seborrhoeic keratoses.
    Hafner C; Vogt T; Landthaler M; Müsebeck J
    Br J Dermatol; 2008 Jul; 159(1):214-7. PubMed ID: 18503601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Genetic basis of seborrheic keratosis and epidermal nevi].
    Hafner C; Hafner H; Groesser L
    Pathologe; 2014 Sep; 35(5):413-23. PubMed ID: 25187080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FGFR3 and PIK3CA mutations in stucco keratosis and dermatosis papulosa nigra.
    Hafner C; Landthaler M; Mentzel T; Vogt T
    Br J Dermatol; 2010 Mar; 162(3):508-12. PubMed ID: 19845664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FGFR3 and PIK3CA mutations are involved in the molecular pathogenesis of solar lentigo.
    Hafner C; Stoehr R; van Oers JM; Zwarthoff EC; Hofstaedter F; Landthaler M; Hartmann A; Vogt T
    Br J Dermatol; 2009 Mar; 160(3):546-51. PubMed ID: 19076977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors.
    Feldman DR; Iyer G; Van Alstine L; Patil S; Al-Ahmadie H; Reuter VE; Bosl GJ; Chaganti RS; Solit DB
    Clin Cancer Res; 2014 Jul; 20(14):3712-20. PubMed ID: 24812411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population.
    Schulten HJ; Salama S; Al-Ahmadi A; Al-Mansouri Z; Mirza Z; Al-Ghamdi K; Al-Hamour OA; Huwait E; Gari M; Al-Qahtani MH; Al-Maghrabi J
    Anticancer Res; 2013 Nov; 33(11):4779-84. PubMed ID: 24222113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncogenic activating mutations are associated with local copy gain.
    Modrek B; Ge L; Pandita A; Lin E; Mohan S; Yue P; Guerrero S; Lin WM; Pham T; Modrusan Z; Seshagiri S; Stern HM; Waring P; Garraway LA; Chant J; Stokoe D; Cavet G
    Mol Cancer Res; 2009 Aug; 7(8):1244-52. PubMed ID: 19671679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
    Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
    Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
    Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
    Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR and KRAS mutational analysis and their correlation to survival in pancreatic and periampullary cancer.
    Oliveira-Cunha M; Hadfield KD; Siriwardena AK; Newman W
    Pancreas; 2012 Apr; 41(3):428-34. PubMed ID: 22422135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Porocarcinomas harbor recurrent HRAS-activating mutations and tumor suppressor inactivating mutations.
    Harms PW; Hovelson DH; Cani AK; Omata K; Haller MJ; Wang ML; Arps D; Patel RM; Fullen DR; Wang M; Siddiqui J; Andea A; Tomlins SA
    Hum Pathol; 2016 May; 51():25-31. PubMed ID: 27067779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spectrum of FGFR3 mutations in multiple intraindividual seborrheic keratoses.
    Hafner C; Hartmann A; Real FX; Hofstaedter F; Landthaler M; Vogt T
    J Invest Dermatol; 2007 Aug; 127(8):1883-5. PubMed ID: 17392824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.
    Kompier LC; Lurkin I; van der Aa MN; van Rhijn BW; van der Kwast TH; Zwarthoff EC
    PLoS One; 2010 Nov; 5(11):e13821. PubMed ID: 21072204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequent activating HRAS mutations in trichilemmoma.
    Tsai JH; Huang WC; Jhuang JY; Jeng YM; Cheng ML; Chiu HY; Kuo KT; Liau JY
    Br J Dermatol; 2014 Nov; 171(5):1073-7. PubMed ID: 24890286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern.
    Hafner C; López-Knowles E; Luis NM; Toll A; Baselga E; Fernández-Casado A; Hernández S; Ribé A; Mentzel T; Stoehr R; Hofstaedter F; Landthaler M; Vogt T; Pujol RM; Hartmann A; Real FX
    Proc Natl Acad Sci U S A; 2007 Aug; 104(33):13450-4. PubMed ID: 17673550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.